Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Environmental Links to Breast Cancer

July 1, 2001
Publication
Article
OncologyONCOLOGY Vol 15 No 7
Volume 15
Issue 7

Two senators have introduced legislationaimed at exploring potential links between environmental exposure and breast

Two senators have introduced legislationaimed at exploring potential links between environmental exposure and breastcancer.

Sens. Harry Reid (D-Nev) and Lincoln Chafee (R-RI) want to give theNational Institute of Environmental Health Sciences (NIEHS) $30 million for thatpurpose. The Institute would use the money to fund eight research centers aroundthe country. 

The Breast Cancer and Environmental Research Act has beenintroduced into the House by Reps. Nita Lowey (D-NY) and Sue Myrick (R-NC). Inan appearance before a Senate appropriations subcommittee in May, NationalCancer Institute Director Richard Klausner said breast cancer deaths per 100,000women have increased from 83 in 1973 to 118 in 1998. Incidence rates areincreasing by about 1% a year for white women and remain unchanged forAfrican-American women. 

Women have a 1-in-8 lifetime risk of contracting breastcancer, and half of the incidence can be explained by currently known riskfactors, such as gene mutations. 

Dr. Klausner did not mention environmentalcauses as potentially contributing to the other half of incidence. Sen. Reid hasexpressed concern about the development of cancer in former nuclear weaponsworkers in Nevada. The NIEHS has considerable experience looking for linksbetween cancer and industrial environments and processes. 

At about the time Sen.Reid was introducing his bill, the NIEHS was releasing a report on a study in1,400 women in the northeast that showed no link between breast cancer and theindustrial chemicals DDT and PCB.

Articles in this issue

Clinical Radiation Oncology
Gemcitabine Active in Patients With Metastatic Breast Cancer
Docetaxel/Carboplatin Combination Produces Impressive Response in Ovarian Cancer Patients
Irinotecan in Lung and Other Malignancies
Excessive Paperwork Detracts From Patient Care, Professional Mentoring, and Research
Once-Yearly Leuprolide for Advanced Prostate Cancer Available
Older Breast Cancer Patients Benefit From Weekly Administration of Paclitaxel
Environmental Links to Breast Cancer
Bush Administration Considering Physician Ratings
Doxorubicin/Paclitaxel Combination Does Not Expose Breast Cancer Patients to Excessive Cardiac Risk
Atrasentan Prolongs Time to Progression in Prostate Cancer Patients
New Clinical Trial to Investigate Treatment Options After Tamoxifen
Prostate Cancer and Spinal Cord Compression
FDA Grants Priority Review to Capecitabine Plus Docetaxel for Breast Cancer
Current Status of Thalidomide in the Treatment of Cancer
Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content
Advertisement

Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.

Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment

ONCOLOGY Staff
June 26th 2025
Article

Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

225AC-3BP-3940 Is Safe, Shows Activity in Heavily Pretreated Advanced Breast Cancer

Gina Mauro
June 24th 2025
Article

Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.


Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC

TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC

Radhika Appaya;Debasish Tripathy;Dejan Juric;Sonia Pernas;Francois Clement Bidard;Kevin Perraud;Louise Emmett;Ana Sofia Ferreira
June 22nd 2025
Article


TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC

TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC

Radhika Appaya;Mario Campone;Louise Emmett;Dejan Juric;Debasish Tripathy;Sonia Pernas;Monica Zuradelli;Kevin Perraud;Aleix Prat
June 21st 2025
Article

Related Content
Advertisement

Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.

Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment

ONCOLOGY Staff
June 26th 2025
Article

Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

225AC-3BP-3940 Is Safe, Shows Activity in Heavily Pretreated Advanced Breast Cancer

Gina Mauro
June 24th 2025
Article

Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.


Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC

TPS 24 Phase Ib Dose-Finding Study of [177Lu]Lu-NeoB + Ribociclib + Fulvestrant in Patients With ER+/HER2− Advanced Breast Cancer With GRPR Expression With Early Relapse FromAdjuvant Endocrine Therapy or Progression on ET + CDK4/6i for ABC

Radhika Appaya;Debasish Tripathy;Dejan Juric;Sonia Pernas;Francois Clement Bidard;Kevin Perraud;Louise Emmett;Ana Sofia Ferreira
June 22nd 2025
Article


TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC

TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC

Radhika Appaya;Mario Campone;Louise Emmett;Dejan Juric;Debasish Tripathy;Sonia Pernas;Monica Zuradelli;Kevin Perraud;Aleix Prat
June 21st 2025
Article

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.